Immunosuppressive drugs on inducing Ag-specific CD4+CD25+Foxp3+ Treg cells during immune response in vivo

Transplant Immunology

Volumn 27, Issue 1, 2012, Pages 30-38

  Wu, Tingting ^a   Zhang, Lianjun ^a   Xu, Kerui ^a   Sun, Chenming ^a   Lei, Tong ^a   Peng, Jianxia ^a   Liu, Guangwei ^a   Wang, Ruoyu ^b   Zhao, Yong ^a  

^a INSTITUTE OF ZOOLOGY   (China)

^b DALIAN UNIVERSITY   (China)

Author keywords

Immunosuppressant; Mouse model; Regulatory T cells; Tolerance

Indexed keywords

CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4 LYMPHOCYTE PERCENTAGE; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVATION; CELL COUNT; CELL FUNCTION; CELL POPULATION; CELL SELECTION; CELL TRANSFER; DRUG INHIBITION; DRUG MECHANISM; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LYMPH NODE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN;

ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; CYCLOPHOSPHAMIDE; CYCLOSPORINE; FORKHEAD TRANSCRIPTION FACTORS; IMMUNE TOLERANCE; IMMUNITY; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; ISOXAZOLES; LYMPH NODES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, TRANSGENIC; MYCOPHENOLIC ACID; OVALBUMIN; PROPYLENE GLYCOLS; SIROLIMUS; SPHINGOSINE; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 84864531704     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2012.05.001     Document Type: Article

References (54)

1. Denton M.D., Magee C.C., Sayegh M.H. Immunosuppressive strategies in transplantation. Lancet 1999, 353:1083-1091.
2. Womer K.L., Vella J.P., Sayegh M.H. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol 2000, 20:126-147.
3. Zheng Y., Rudensky A.Y. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007, 8:457-462.
4. Salama A.D., Remuzzi G., Harmon W.E., Sayegh M.H. Challenges to achieving clinical transplantation tolerance. J Clin Invest 2001, 108:943-948.
5. Li W., Kuhr C.S., Zheng X.X., Carper K., Thomson A.W., Reyes J.D., et al. New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells. Am J Transplant 2008, 8:1639-1651.
6. Zhao Y. The different effects of cyclosporin A and rapamycin on regulatory CD4+CD25+ T cells: potential relationship with transplant tolerance induction. Expert Rev Clin Immunol 2007, 3:245-249.
7. Asiedu C.K., Goodwin K.J., Balgansuren G., Jenkins S.M., Le Bas-Bernardet S., Jargal U., et al. Elevated T regulatory cells in long-term stable transplant tolerance in rhesus macaques induced by anti-CD3 immunotoxin and deoxyspergualin. J Immunol 2005, 175:8060-8068.
8. Qu Y., Zhang B., Zhao L., Liu G., Ma H., Rao E., et al. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice. Transpl Immunol 2007, 17:153-161.
9. Segundo D.S., Ruiz J.C., Izquierdo M., Fernandez-Fresnedo G., Gomez-Alamillo C., Merino R., et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006, 82:550-557.
10. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.
11. Wang H., Zhao L., Sun Z., Sun L., Zhang B., Zhao Y. A potential side effect of cyclosporin A: inhibition of CD4(+)CD25(+) regulatory T cells in mice. Transplantation 2006, 82:1484-1492.
12. Blazar B.R., Taylor P.A., Panoskaltsis-Mortari A., Vallera D.A. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol 1998, 160:5355-5365.
13. Birck R., Newman M., Braun C., Neumann I., Nemoto K., Yard B., et al. 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis. Nephrol Dial Transplant 2006, 21:58-63.
14. Zoja C., Benigni A., Noris M., Corna D., Casiraghi F., Pagnoncelli M., et al. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 2001, 60:653-663.
15. Zhang L., Qi Z., Wu D., Shan S., Ekberg H. Additive effects of leflunomide and tacrolimus in prevention of islet xenograft rejection. Scand J Immunol 2004, 59:255-260.
16. Weigmann B., Jarman E.R., Sudowe S., Bros M., Knop J., Reske-Kunz A.B. Induction of regulatory T cells by leflunomide in a murine model of contact allergen sensitivity. J Invest Dermatol 2006, 126:1524-1533.
17. Schuster K., Gadiot J., Andreesen R., Mackensen A., Gajewski T.F., Blank C. Homeostatic proliferation of naive CD8+ T cells depends on CD62L/l-selectin-mediated homing to peripheral LN. Eur J Immunol 2009, 39:2981-2990.
18. Wolf A.M., Eller K., Zeiser R., Durr C., Gerlach U.V., Sixt M., et al. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol 2009, 183:3751-3760.
19. Bracci L., Moschella F., Sestili P., La Sorsa V., Valentini M., Canini I., et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007, 13:644-653.
20. Su Y.C., Rolph M.S., Cooley M.A., Sewell W.A. Cyclophosphamide augments inflammation by reducing immunosuppression in a mouse model of allergic airway disease. J Allergy Clin Immunol 2006, 117:635-641.
21. Zheng Q., Xu Y., Liu Y., Zhang B., Li X., Guo F., et al. Induction of Foxp3 demethylation increases regulatory CD4+CD25+ T cells and prevents the occurrence of diabetes in mice. J Mol Med (Berl) 2009, 87:1191-1205.
22. Wells A.D., Li X.C., Li Y., Walsh M.C., Zheng X.X., Wu Z., et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999, 5:1303-1307.
23. Zhang L., Zhao Y. The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J Cell Physiol 2007, 211:590-597.
24. Strauss L., Czystowska M., Szajnik M., Mandapathil M., Whiteside T.L. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One 2009, 4:e5994.
25. Strauss L., Whiteside T.L., Knights A., Bergmann C., Knuth A., Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007, 178:320-329.
26. Dahlberg P.E., Schartner J.M., Timmel A., Seroogy C.M. Daily subcutaneous injections of peptide induce CD4+ CD25+ T regulatory cells. Clin Exp Immunol 2007, 149:226-234.
27. Schartner J.M., Singh A.M., Dahlberg P.E., Nettenstrom L., Seroogy C.M. Recurrent superantigen exposure in vivo leads to highly suppressive CD4+CD25+ and CD4+CD25- T cells with anergic and suppressive genetic signatures. Clin Exp Immunol 2009, 155:348-356.
28. Agarwal A., Newell K.A. The role of positive costimulatory molecules in transplantation and tolerance. Curr Opin Organ Transplant 2008, 13:366-372.
29. Kang S.M., Tang Q., Bluestone J.A. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant 2007, 7:1457-1463.
30. You S., Leforban B., Garcia C., Bach J.F., Bluestone J.A., Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 2007, 104:6335-6340.
31. Carlson R.P., Hartman D.A., Tomchek L.A., Walter T.L., Lugay J.R., Calhoun W., et al. Rapamycin, a potential disease-modifying antiarthritic drug. J Pharmacol Exp Ther 1993, 266:1125-1138.
32. Oliveira J.G., Xavier P., Sampaio S.M., Henriques C., Tavares I., Mendes A.A., et al. Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days post-kidney transplantation. Transplantation 2002, 73:915-920.
33. Dodge I.L., Demirci G., Strom T.B., Li X.C. Rapamycin induces transforming growth factor-beta production by lymphocytes. Transplantation 2000, 70:1104-1106.
34. Huynh M.L., Fadok V.A., Henson P.M. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002, 109:41-50.
35. Malek T.R., Bayer A.L. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004, 4:665-674.
36. Thornton A.M., Donovan E.E., Piccirillo C.A., Shevach E.M. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004, 172:6519-6523.
37. Aoki C.A., Roifman C.M., Lian Z.X., Bowlus C.L., Norman G.L., Shoenfeld Y., et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun 2006, 27:50-53.
38. Zeiser R., Leveson-Gower D.B., Zambricki E.A., Kambham N., Beilhack A., Loh J., et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008, 111:453-462.
39. Molhoek K.R., McSkimming C.C., Olson W.C., Brautigan D.L., Slingluff C.L. Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother 2009, 58:867-876.
40. Procaccini C., De Rosa V., Galgani M., Abanni L., Cali G., Porcellini A., et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 2010, 33:929-941.
41. Wang Y., Camirand G., Lin Y., Froicu M., Deng S., Shlomchik W.D., Lakkis F.G., Rothstein D.M. Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice. J Immunol 2011, 186:2809-2818.
42. Lim D.G., Koo S.K., Park Y.H., Kim Y., Kim H.M., Park C.S., Kim S.C., Han D.J. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation. Transplantation 2010, 89:928-936.
43. Gandolfo M.T., Jang H.R., Bagnasco S.M., Ko G.J., Agreda P., Soloski M.J., Crow M.T., Rabb H. Mycophenolate mofetil modifies kidney tubular injury and Foxp3+ regulatory T cell trafficking during recovery from experimental ischemia-reperfusion. Transpl Immunol 2010, 23:45-52.
44. Zeiser R., Nguyen V.H., Beilhack A., Buess M., Schulz S., Baker J., et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108:390-399.
45. Rooney P.H., Telfer C., McFadyen M.C., Melvin W.T., Murray G.I. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr Cancer Drug Targets 2004, 4:257-265.
46. Brode S., Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 2008, 28:109-126.
47. Ghiringhelli F., Menard C., Puig P.E., Ladoire S., Roux S., Martin F., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007, 56:641-648.
48. Audia S., Nicolas A., Cathelin D., Larmonier N., Ferrand C., Foucher P., et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 2007, 150:523-530.
49. Zhao J., Cao Y., Lei Z., Yang Z., Zhang B., Huang B. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 2010, 70:4850-4858.
50. Baan C.C., van der Mast B.J., Klepper M., Mol W.M., Peeters A.M., Korevaar S.S., et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005, 80:110-117.
51. Coenen J.J., Koenen H.J., van Rijssen E., Hilbrands L.B., Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006, 107:1018-1023.
52. Liu G, Yang K, Burns S, Shrestha S, Chi H. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol 11:1047-56.
53. Sauer S., Bruno L., Hertweck A., Finlay D., Leleu M., Spivakov M., et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008, 105:7797-7802.
54. Haxhinasto S., Mathis D., Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008, 205:565-574.